Bayer: Breast Neoplasms trials
The registry lists 19 Breast Neoplasms studies with Bayer as lead sponsor. 1 are open to participants now and 6 have results posted.
Phase 1 3Phase 2 11Phase 3 3No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)RecruitingNCT06760819Phase 2
- Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast CancerTerminatedNCT02258464Phase 2Results posted
- Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast CancerCompletedNCT02258451Phase 2Results posted
- Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast CancerCompletedNCT01234337Phase 3Results posted
- Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)CompletedNCT01104584Phase 3Results posted
- Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRICompletedNCT01067976Phase 3Results posted
- BAY43-9006 - Phase II in Advanced Breast CancerCompletedNCT00101400Phase 2Results posted
- A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 ProteinCompletedNCT04147819Phase 1
- Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its SafetyCompletedNCT04125693Phase 2
- A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsCompletedNCT02576431Phase 2
- Phase I Study of Oral BAY 1217389 in Combination With Intravenous PaclitaxelCompletedNCT02366949Phase 1
- Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous PaclitaxelTerminatedNCT02138812Phase 1
- Study to Investigate Adherence of Patients to Clodronate (Bonefos) TreatmentCompletedNCT01198457
- BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant DiseaseCompletedNCT01070485Phase 2
- Bonefos and the Consumption of AnalgesicsCompletedNCT00909142
- ZK 230211 in Postmenopausal Woman With Metastatic Breast CancerCompletedNCT00555919Phase 2
- Evaluation of a New Agent for Treatment of Advanced Stage Breast CancerCompletedNCT00313248Phase 2
- Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast CancerCompletedNCT00288249Phase 2
- Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer PatientsCompletedNCT00044525Phase 2